1-8 of 8
Thierry Gorlia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

C. Mircea S. Tesileanu, Marc Sanson, Wolfgang Wick, Alba A. Brandes, Paul M. Clement, Sara C. Erridge, Michael A. Vogelbaum, Anna K. Nowak, Jean-Francois Baurain, Warren P. Mason, Helen Wheeler, Olivier L. Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Myra E. van Linde, Kenneth Aldape, Robert B. Jenkins, Johan M. Kros, Pieter Wesseling, Andreas von Deimling, Youri Hoogstrate, Iris de Heer, Peggy N. Atmodimedjo, Hendrikus J. Dubbink, Rutger W.W. Brouwer, Wilfred F.J. van IJcken, Kin Jip Cheung, Vassilis Golfinopoulos, Brigitta G. Baumert, Thierry Gorlia, Pim J. French, Martin J. van den Bent
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2527–2535.
https://doi.org/10.1158/1078-0432.CCR-21-4283
Published: 13 June 2022
View article titled, Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <em>IDH</em>-wildtype: <em>Post Hoc</em> Analysis of the EORTC Randomized Phase III CATNON Trial
Open the PDF for Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <em>IDH</em>-wildtype: <em>Post Hoc</em> Analysis of the EORTC Randomized Phase III CATNON Trial in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Kaspar Draaisma, C. Mircea S. Tesileanu, Iris de Heer, Martin Klein, Marion Smits, Jaap C. Reijneveld, Paul M. Clement, Filip Y.F. de Vos, Antje Wick, Paul J. Mulholland, Martin J.B. Taphoorn, Michael Weller, Olivier L. Chinot, Johan M. Kros, Tina Verschuere, Corneel Coens, Vassilis Golfinopoulos, Thierry Gorlia, Ahmed Idbaih, Pierre A. Robe, Martin J. van den Bent, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2440–2448.
https://doi.org/10.1158/1078-0432.CCR-21-3725
Published: 01 June 2022
View article titled, Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Open the PDF for Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial in another window
Includes: Supplementary data
Journal Articles

Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

Julia Furtner, Michael Weller, Michael Weber, Thierry Gorlia, Burt Nabors, David A. Reardon, Joerg C. Tonn, Roger Stupp, Matthias Preusser
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 129–136.
https://doi.org/10.1158/1078-0432.CCR-21-1987
Published: 05 January 2022
View article titled, Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials
Open the PDF for Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials in another window
Includes: Supplementary data
Journal Articles

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Monika E. Hegi, Els Genbrugge, Thierry Gorlia, Roger Stupp, Mark R. Gilbert, Olivier L. Chinot, L. Burt Nabors, Greg Jones, Wim Van Criekinge, Josef Straub, Michael Weller
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1809–1816.
https://doi.org/10.1158/1078-0432.CCR-18-3181
Published: 15 March 2019
View article titled, <em>MGMT</em> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
Open the PDF for <em>MGMT</em> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Wolfgang Wick, Thierry Gorlia, Pierre Bady, Michael Platten, Martin J. van den Bent, Martin J.B. Taphoorn, Jonathan Steuve, Alba A. Brandes, Marie-France Hamou, Antje Wick, Markus Kosch, Michael Weller, Roger Stupp, Patrick Roth, Vassilis Golfinopoulos, Jean-Sebastien Frenel, Mario Campone, Damien Ricard, Christine Marosi, Salvador Villa, Astrid Weyerbrock, Kirsten Hopkins, Krisztian Homicsko, Benoit Lhermitte, Gianfranco Pesce, Monika E. Hegi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4797–4806.
https://doi.org/10.1158/1078-0432.CCR-15-3153
Published: 02 October 2016
View article titled, Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <em>MGMT</em> Promoter Hypermethylation (EORTC 26082)
Open the PDF for Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <em>MGMT</em> Promoter Hypermethylation (EORTC 26082) in another window
Includes: Supplementary data
Journal Articles

MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Martin J. van den Bent, Lale Erdem-Eraslan, Ahmed Idbaih, Johan de Rooi, Paul H.C. Eilers, Wim G.M. Spliet, Wilfred F.A. den Dunnen, Cees Tijssen, Pieter Wesseling, Peter A.E. Sillevis Smitt, Johan M. Kros, Thierry Gorlia, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5513–5522.
https://doi.org/10.1158/1078-0432.CCR-13-1157
Published: 01 October 2013
View article titled, <em>MGMT</em>-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951
Open the PDF for <em>MGMT</em>-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951 in another window
Includes: Supplementary data
Journal Articles

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Lariesa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbaih, Marc Sanson, Peter A.E. Sillevis Smitt, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 7148–7155.
https://doi.org/10.1158/1078-0432.CCR-11-1274
Published: 14 November 2011
View article titled, A Hypermethylated Phenotype Is a Better Predictor of Survival than <em>MGMT</em> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
Open the PDF for A Hypermethylated Phenotype Is a Better Predictor of Survival than <em>MGMT</em> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951 in another window
Includes: Supplementary data
Journal Articles

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Cees C. Tijssen, Denis Lacombe, Ahmed Idbaih, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, Marc Sanson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1597–1604.
https://doi.org/10.1158/1078-0432.CCR-09-2902
Published: 28 February 2010
View article titled, <em>IDH1</em> and <em>IDH2</em> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Open the PDF for <em>IDH1</em> and <em>IDH2</em> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group in another window